Literature DB >> 22752494

Friedreich ataxia clinical outcome measures: natural history evaluation in 410 participants.

Sean R Regner1, Nicholas S Wilcox, Lisa S Friedman, Lauren A Seyer, Kim A Schadt, Karlla W Brigatti, Susan Perlman, Martin Delatycki, George R Wilmot, Christopher M Gomez, Khalaf O Bushara, Katherine D Mathews, S H Subramony, Tetsuo Ashizawa, Bernard Ravina, Alicia Brocht, Jennifer M Farmer, David R Lynch.   

Abstract

Friedreich ataxia is an autosomal recessive neurodegenerative disorder characterized by ataxia, dysarthria, and areflexia. The authors report the progress of a large international noninterventional cohort (n = 410), tracking the natural history of disease progression using the neurologic examination-based Friedreich Ataxia Rating Scale. The authors analyzed the rate of progression with cross-sectional analysis and longitudinal analysis over a 2-year period. The Friedreich Ataxia Rating Scale captured disease progression when used at 1 and 2 years following initial evaluation, with a lower ratio of standard deviation of change to mean change over 2 years of evaluation. However, modeling of disease progression identified substantial ceiling effects in the Friedreich Ataxia Rating Scale, suggesting this measure is most useful in subjects before maximal deficit is approached.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22752494      PMCID: PMC3674496          DOI: 10.1177/0883073812448462

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  19 in total

Review 1.  Friedreich ataxia: effects of genetic understanding on clinical evaluation and therapy.

Authors:  David R Lynch; Jennifer M Farmer; Laura J Balcer; Robert B Wilson
Journal:  Arch Neurol       Date:  2002-05

2.  Atypical Friedreich ataxia caused by compound heterozygosity for a novel missense mutation and the GAA triplet-repeat expansion.

Authors:  S I Bidichandani; T Ashizawa; P I Patel
Journal:  Am J Hum Genet       Date:  1997-05       Impact factor: 11.025

3.  The natural history of degenerative ataxia: a retrospective study in 466 patients.

Authors:  T Klockgether; R Lüdtke; B Kramer; M Abele; K Bürk; L Schöls; O Riess; F Laccone; S Boesch; I Lopes-Cendes; A Brice; R Inzelberg; N Zilber; J Dichgans
Journal:  Brain       Date:  1998-04       Impact factor: 13.501

4.  How is disease progress in Friedreich's ataxia best measured? A study of four rating scales.

Authors:  M C Fahey; L Corben; V Collins; A J Churchyard; M B Delatycki
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-10-20       Impact factor: 10.154

5.  Measuring Friedreich ataxia: complementary features of examination and performance measures.

Authors:  D R Lynch; J M Farmer; A Y Tsou; S Perlman; S H Subramony; C M Gomez; T Ashizawa; G R Wilmot; R B Wilson; L J Balcer
Journal:  Neurology       Date:  2006-06-13       Impact factor: 9.910

Review 6.  Molecular pathogenesis of Friedreich ataxia.

Authors:  M Pandolfo
Journal:  Arch Neurol       Date:  1999-10

7.  L-carnitine and creatine in Friedreich's ataxia. A randomized, placebo-controlled crossover trial.

Authors:  L Schöls; J Zange; M Abele; M Schillings; G Skipka; S Kuntz-Hehner; M C P van Beekvelt; W N J M Colier; K Müller; T Klockgether; H Przuntek; M Vorgerd
Journal:  J Neural Transm (Vienna)       Date:  2004-10-12       Impact factor: 3.575

8.  Clinical and genetic abnormalities in patients with Friedreich's ataxia.

Authors:  A Dürr; M Cossee; Y Agid; V Campuzano; C Mignard; C Penet; J L Mandel; A Brice; M Koenig
Journal:  N Engl J Med       Date:  1996-10-17       Impact factor: 91.245

9.  Very-late-onset Friedreich ataxia with disturbing head tremor and without spinal atrophy--a case report.

Authors:  Aekaterini Galimanis; Louis Glutz; Jean-Marc Burgunder; Roland Spiegel; Alain Kaelin-Lang
Journal:  Mov Disord       Date:  2008-05-15       Impact factor: 10.338

10.  Friedreich's ataxia: point mutations and clinical presentation of compound heterozygotes.

Authors:  M Cossée; A Dürr; M Schmitt; N Dahl; P Trouillas; P Allinson; M Kostrzewa; A Nivelon-Chevallier; K H Gustavson; A Kohlschütter; U Müller; J L Mandel; A Brice; M Koenig; F Cavalcanti; A Tammaro; G De Michele; A Filla; S Cocozza; M Labuda; L Montermini; J Poirier; M Pandolfo
Journal:  Ann Neurol       Date:  1999-02       Impact factor: 10.422

View more
  17 in total

1.  Friedreich's Ataxia related Diabetes: Epidemiology and management practices.

Authors:  Jaclyn Tamaroff; Anna DeDio; Kristin Wade; McKenzie Wells; Courtney Park; Karla Leavens; Christian Rummey; Andrea Kelly; David R Lynch; Shana E McCormack
Journal:  Diabetes Res Clin Pract       Date:  2022-03-14       Impact factor: 8.180

2.  FXN Promoter Silencing in the Humanized Mouse Model of Friedreich Ataxia.

Authors:  Yogesh K Chutake; Whitney N Costello; Christina C Lam; Aniruddha C Parikh; Tamara T Hughes; Michael G Michalopulos; Mark A Pook; Sanjay I Bidichandani
Journal:  PLoS One       Date:  2015-09-22       Impact factor: 3.240

3.  Friedreich Ataxia and nephrotic syndrome: a series of two patients.

Authors:  Julianna E Shinnick; Charles J Isaacs; Sharon Vivaldi; Kimberly Schadt; David R Lynch
Journal:  BMC Neurol       Date:  2016-01-12       Impact factor: 2.474

4.  Reversal of epigenetic promoter silencing in Friedreich ataxia by a class I histone deacetylase inhibitor.

Authors:  Yogesh K Chutake; Christina C Lam; Whitney N Costello; Michael P Anderson; Sanjay I Bidichandani
Journal:  Nucleic Acids Res       Date:  2016-02-20       Impact factor: 16.971

5.  Progression of Friedreich ataxia: quantitative characterization over 5 years.

Authors:  Maya Patel; Charles J Isaacs; Lauren Seyer; Karlla Brigatti; Sarah Gelbard; Cassandra Strawser; Debbie Foerster; Julianna Shinnick; Kimberly Schadt; Eppie M Yiu; Martin B Delatycki; Susan Perlman; George R Wilmot; Theresa Zesiewicz; Katherine Mathews; Christopher M Gomez; Grace Yoon; Sub H Subramony; Alicia Brocht; Jennifer Farmer; David R Lynch
Journal:  Ann Clin Transl Neurol       Date:  2016-07-25       Impact factor: 4.511

Review 6.  Mitochondrial iron-sulfur cluster biogenesis from molecular understanding to clinical disease.

Authors:  Majid Alfadhel; Marwan Nashabat; Qais Abu Ali; Khalid Hundallah
Journal:  Neurosciences (Riyadh)       Date:  2017-01       Impact factor: 0.906

Review 7.  Degenerative Ataxias: challenges in clinical research.

Authors:  Sub H Subramony
Journal:  Ann Clin Transl Neurol       Date:  2016-11-17       Impact factor: 4.511

8.  Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia.

Authors:  David R Lynch; Jennifer Farmer; Lauren Hauser; Ian A Blair; Qing Qing Wang; Clementina Mesaros; Nathaniel Snyder; Sylvia Boesch; Melanie Chin; Martin B Delatycki; Paola Giunti; Angela Goldsberry; Chad Hoyle; Michael G McBride; Wolfgang Nachbauer; Megan O'Grady; Susan Perlman; S H Subramony; George R Wilmot; Theresa Zesiewicz; Colin Meyer
Journal:  Ann Clin Transl Neurol       Date:  2018-11-10       Impact factor: 4.511

9.  Frataxin levels in peripheral tissue in Friedreich ataxia.

Authors:  Michael Lazaropoulos; Yina Dong; Elisia Clark; Nathaniel R Greeley; Lauren A Seyer; Karlla W Brigatti; Carlton Christie; Susan L Perlman; George R Wilmot; Christoper M Gomez; Katherine D Mathews; Grace Yoon; Theresa Zesiewicz; Chad Hoyle; Sub H Subramony; Alicia F Brocht; Jennifer M Farmer; Robert B Wilson; Eric C Deutsch; David R Lynch
Journal:  Ann Clin Transl Neurol       Date:  2015-07-01       Impact factor: 4.511

10.  Impact of diabetes in the Friedreich ataxia clinical outcome measures study.

Authors:  Ashley McCormick; Jennifer Farmer; Susan Perlman; Martin Delatycki; George Wilmot; Katherine Matthews; Grace Yoon; Chad Hoyle; Sub H Subramony; Theresa Zesiewicz; David R Lynch; Shana E McCormack
Journal:  Ann Clin Transl Neurol       Date:  2017-07-26       Impact factor: 4.511

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.